FUNDACAO ANTONIO PRUDENTE

Their core work

Fundação Antônio Prudente runs the A.C. Camargo Cancer Center in São Paulo, one of Latin America's largest oncology hospitals combining clinical treatment, teaching, and cancer research. They contribute clinical expertise, patient cohorts, and tumor data to international cancer studies, particularly in rare cancers and cancers with high regional incidence in South America. Their value in EU consortia comes from access to Latin American patient populations and tumor biobanks that European partners cannot replicate locally. They work across diagnostics, translational genomics, and screening technologies for solid tumors.

What they specialise in

How they've shifted over time

All three H2020 projects started in 2019, so early-versus-recent analysis is limited — this represents a single wave of international engagement rather than a multi-year evolution. Within that 2019 cohort, their work spans a coherent oncology portfolio: from technology-led screening (gastric cancer breath sensors) to clinical and translational studies in rare tumors and head and neck cancer. The pattern suggests a deliberate strategy of joining EU-Latin America bridge projects rather than drifting between topics.

Heading toward translational, genetics-informed clinical cancer research with Latin American cohorts, making them a natural partner for consortia needing South American patient data.

How they like to work

They consistently join as a participant rather than lead, contributing a specific clinical and geographic asset — Brazilian patient cohorts and oncology expertise — to European-led consortia. All three projects are large international networks (40 partners across 22 countries combined), suggesting they fit best in broad, multi-country research alliances rather than tight small-team collaborations. Expect reliable clinical-site delivery rather than project coordination.

Connected to 40 unique partners across 22 countries, with a distinctive EU–Latin America bridge function given their São Paulo base. Their network is broad rather than concentrated, typical of a regional anchor institution in multi-continental cancer consortia.

What sets them apart

They are one of the very few non-European cancer centers appearing repeatedly in H2020 health consortia, and the dominant Brazilian oncology partner in these networks. Their value is not a specific technology but irreplaceable access — Latin American tumor samples, patient cohorts, and regional cancer epidemiology that European hospitals cannot provide. For any EU project studying cancers where South American incidence or genetic diversity matters, they are effectively a default partner.

Highlights from their portfolio

• HEADSpAcE
  Long-running (2019-2024) translational study explicitly built around the South America–Europe axis where A.C. Camargo's cohorts are central.
• SELNET
  Uses sarcoma as a model to build a European–Latin American network for rare tumor care, positioning them as a regional reference center.
• VOGAS
  Unusual combination of engineering (hybrid breath sensors) with their clinical oncology role — shows willingness to support device-development trials, not only observational studies.